Sun Pharmaceutical Industries Limited
SUNPHARMA.BO
₹1900.75
▲ 0.14%
Sun Pharma shares were nearly flat, up just 0.14%, as the stock continues to trade in a range about 7% below its 52-week high of Rs 2,047 and 23% above its low of Rs 1,548. The past year has actually been decent for shareholders with an 18-19% return, even as the pharma major's trailing valuation looks stretched relative to peers. The key cloud on the horizon is the threat of biosimilar competition to Ilumya entering the market in FY27-28, a risk that analysts have flagged as a potential drag on future growth. Despite that overhang, the consensus among 38 analysts remains a "buy" with an average target of Rs 1,963.26, not far from the current 12-month target estimate of around Rs 2,051.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -16.45% | -16.45% | -16.45% | -16.45% |
Analyst Consensus
Average Target Price: ₹1963.26 (range ₹1550.00 - ₹2450.00) based on 38 analysts
Strong Buy: 10
Buy: 24
Hold: 0
Sell: 2
Strong Sell: 2
Related News
| Nov 5, 2025 | India's Sun Pharma Exec Says Open To Considering (Expanding) Manufacturing Presence In The U.S. |
No comments:
Post a Comment